Q-omics provides the consensus-scored ANKRD36BP2 profile across patient tissues and cancer cell-line models. ANKRD36BP2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ANKRD36BP2 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, ANKRD36BP2 RNA expression shows 18,147 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, COAD, and GBM as cancer lineages where ANKRD36BP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD36BP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD36BP2 survival associations across molecular data types. ANKRD36BP2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD36BP2 RNA expression–survival associations across cancer types. High ANKRD36BP2 expression shows unfavorable associations in KIRC and UVM, but favorable associations in HNSC, SKCM, LUAD and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ANKRD36BP2 RNA expression.
This table summarizes ANKRD36BP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD36BP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD36BP2 shows lower tumor expression in COAD, READ and UCEC and higher tumor expression in LUAD, HNSC and THCA. The COAD box plot shows higher ANKRD36BP2 RNA expression in normal versus tumor tissue (log2 FC = −0.822, t-test p < 0.001).
This table shows molecular features associated with ANKRD36BP2 in patient tissues and cancer cell lines. In patient samples, ANKRD36BP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD36BP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
